Video

Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung Cancer

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

The addition of radiation to checkpoint inhibitors may boost the clinical outcomes of patients with lung cancer. Experts are questioning whether administering radiation therapy during treatment with a PD-1/PD-L1 inhibitor could provide significant responses to checkpoint blockade in these patients.

Sampath says that adverse events with radiation are often limited to where the radiation took place. Both radiation and immunotherapy can cause lung side effects and inflammation. In targeting the cancer cells with either radiation or immunotherapy, the health of the surrounding cells must be taken into consideration, Sampath says. If the treatment becomes too potent for the surrounding cells, side effects such as pneumonitis can occur, especially with radiation.

Combining radiation with immunotherapy is a relatively new technique, and Sampath says that understanding the efficacy and side effects of the regimen will come with experience.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.